Skip to content

Lung cAncer Robotic Comparative Study

Comparing Outcomes for Minimally Invasive Techniques for Anatomic Lung Resection for Cancer - A Prospective, Comparative, Non-randomized, Open Label Post-market Observational Cohort Study Within Europe

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06038227
Acronym
LARCS
Enrollment
600
Registered
2023-09-14
Start date
2023-07-15
Completion date
2027-12-30
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Keywords

Minimally invasive surgery, Robotics

Brief summary

To compare outcomes of minimally invasive surgical techniques for the treatment of early-stage non-small cell lung cancer.

Detailed description

Detection of lung cancer is occurring at increasingly earlier stages due to improved screening and the discovery of incidental nodules. Coinciding with this trend is recent data from two international randomized, control trials, RAVAL - (Robotic Lobectomy vs. Thoracoscopic Lobectomy for Early Stage Lung Cancer) and, JCOG0802 (The Japan Clinical Oncology Group) that show oncologic outcomes from segmentectomy are equivalent to lobectomy for cancers ≤2 cm. However, segmentectomy is a more complex technical operation that may not be easily feasible using video assisted thoracic surgery (VATS) but could be facilitated by robotic-assisted thoracic surgery (RATS), allowing improved vision, precision and controlled anatomic dissection. The LARCS study is designed to understand the perioperative outcomes of patients and identify the real-world selection process of either VATS and RATS segmentectomy and lobectomy for lung cancers ≤2 cm. It aims to generate evidence to support integration of patient-centered care using minimally invasive technology. In addition, health related quality of life captured in the study will also provide valuable insight into time to recovery, determining burden of the disease, and guide future treatment strategy.

Interventions

PROCEDURERobotic Assisted Thoracic Surgery

Surgeons will pre-determine to perform a segmentectomy or lobectomy using RATS.

PROCEDUREVideo Assisted Thoracic Surgery

Surgeons will pre-determine to perform a segmentectomy or lobectomy using VATS.

Sponsors

Intuitive Surgical
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient diagnosed with clinical stage IA1-2 non-small cell lung cancer at time of procedure * Patient scheduled to undergo minimally invasive surgery for NSCLC with either da Vinci robotic assisted surgery or VATs * Aged ≥ 18 years * Must be willing and able to comply with study requirements * Must indicate their understanding of the study and willingness to participate by signing an appropriate informed consent form

Exclusion criteria

* Patients with clinical stage IA3, II, III, and IV lung cancer * Patient receiving a lobectomy/segmentectomy as an emergency procedure * Patients receiving a lobectomy/segmentectomy for metastatic cancer * Patients scheduled to receive a bilobectomy or sleeve-lobectomy * Mental incapacity to understand or consent to study procedures * Anticipated difficulty for patient to comply with protocol requirements * Unable to comply with the follow up schedule * Pregnant or are planning to become pregnant during the study * Life expectancy \< 12 months

Design outcomes

Primary

MeasureTime frameDescription
Patient reported Quality of Life 11 month post surgeryEQ 5D 5L (European Quality of Life Five Dimension) The EQ-5D-5L is a validated and established generic Patient Reported Outcome (PRO) instrument that uses 6 questions to assess patients' quality of life. It includes a vertical EQ visual analog scale (EQ VAS, 0-100 points) and a descriptive EQ-5D-5L system. An algorithm is used to calculate the scores. For the descriptive section of the scale, an index value of 1 represents the best possible health state, while an index value of \<0 (variable) represents the worst possible health state. The EQ VAS score is rated on a scale of 0-100 points. 0 points correspond to the worst possible health status, while 100 points correspond to the best possible health status.
Patient reported Quality of Life 21 month post surgeryRNLI (Reintegration to Normal Living Index) The RNLI has 11 questions and is scored on a visual analogue scale (VAS). On one end: "does not describe my situation" (1 or minimal integration) and "fully describes my situation" (10 or complete integration). Individual item scores are summed to provide the total score. The higher the score, the better the patients perceived integration.

Secondary

MeasureTime frameDescription
Number of conversions from pre-operative surgical planimmediately post operativeNumber of participants who undergo conversion surgery from the pre-operative surgical plan captured on the surgical decision making form. Conversion may be from segmentectomy to lobetomy, RATS or VATS to open surgery.

Countries

Denmark, France, Germany, Italy, Norway, Switzerland, United Kingdom

Contacts

CONTACTMarie Allouis
Marie.Allouis@intusurg.com+33786480495
CONTACTJames Grainger
james.grainger@intusurg.com
PRINCIPAL_INVESTIGATORTom Routledge

Guy's St Thomas' NHS Foundation Trust, UK

PRINCIPAL_INVESTIGATORRune Eggum

University Hospital, Akershus

PRINCIPAL_INVESTIGATORMartin Eichhorn

Thoraxklinik Heidelberg, Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 15, 2026